DERM
Journey Medical Corporation
Healthcare · Drug Manufacturers - Specialty & Generic · NCM
$5.97
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$175M
Total market value of the company
-106.00
Based on estimated future earnings — lower means cheaper
Rev Growth
+21.5%
Year-over-year revenue change
Profit Margin
-14.8%
How much profit the company keeps from each dollar of revenue
-36.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$13.50
+126% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 4 analysts covering this stock
About Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

https://journeymedicalcorp.com

Country: United States Employees: 58 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
17.7% PASS
Debt must be below 33% of total assets
Cash Ratio
16.7% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
0.736
Good returns relative to risk taken
0.0439
Modest edge detected — smaller position warranted
0.583
Acceptable balance between returns and drawdown risk
Annual Return
30.7%
Historical annualised return based on price data
-52.6%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
7
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

1.04
Moves slightly more than the broader market
52W High
$9.56
38% below the year high
52W Low
$4.31
39% above the year low
Avg Volume
238,945
Average daily shares traded — higher means easier to buy and sell
17.6
Days it would take all short sellers to cover — higher means more crowded
Short % Float
24.5%
Very high short interest — potential squeeze candidate
0.0%
Annual dividend as a percentage of the share price
$-0.47
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

0.83
Moderate leverage — manageable
1.72
Healthy liquidity position
Quick Ratio
1.38
Like current ratio but excludes inventory — stricter test
Gross Margin
65.4%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-9.3%
Profit from core operations before interest and tax
$-3,300,375
Negative — the business is spending more than it generates
Revenue (TTM)
$65M
Total revenue over the last 12 months
Net Income
$-9,588,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
4
Target High
$16.00
Target Median
$13.50
Target Low
$12.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-04-22 MARAOUI CLAUDE Chief Executive Officer 49,277
2026-04-22 BENESCH JOSEPH Chief Financial Officer 28,907
2026-04-22 ALLOUSH RAMSEY Chief Operating Officer 46,863
2025-08-25 MARAOUI CLAUDE Chief Executive Officer 1,250,000 $81,250
2025-08-05 ROSENWALD LINDSAY A Director 50,000
2025-08-05 PEARCE MICHAEL COOPER Director 20,000
2025-08-05 HERSKOWITZ NEIL Director 20,000
2025-08-05 TOLEDANO MIRANDA JAYNE Director 20,000
2025-08-05 SMITH JUSTIN ADAM Director 20,000
2025-06-25 ROSENWALD LINDSAY A Director 7,173
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.